Enhanced interaction between natural killer cells and lung cancer cells: Involvement in gefitinib-mediated immunoregulation

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  He, Sisi ^a   Yin, Tao ^a   Li, Dan ^a   Gao, Xiang ^a   Wan, Yang ^a   Ma, Xuelei ^a   Ye, Tinghong ^a   Guo, Fuchun ^a   Sun, Jianhong ^a   Lin, Ziqiang ^a   Wang, Yongsheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

EGFR; Gefitinib; Immunotherapy; Natural killer cells; NSCLC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; GEFITINIB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN ANTIBODY; PROTEIN LC3; PROTEIN MICA; PROTEIN ULBP1; PROTEIN ULBP2; SOMATOMEDIN B RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CELL INTERACTION; CELL STRAIN A549; CELL STRAIN H1975; CONTROLLED STUDY; DEGRANULATION; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; LUNG CANCER; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; WILD TYPE;

AUTOPHAGY; CELL COMMUNICATION; CELL DEGRANULATION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOMODULATION; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LIGANDS; LUNG NEOPLASMS; MUTATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 2; STAT3 TRANSCRIPTION FACTOR;

EID: 84881288707     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-186     Document Type: Article

References (48)

1. Kohler BA, Ward E, McCarthy BJ, Schymura MJ, Ries LA, Eheman C, Jemal A, Anderson RN, Ajani UA, Edwards BK. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011, 103:714-736. 10.1093/jnci/djr077, 3086878, 21454908.
2. Tracy S, Mukohara T, Hansen M, Meyerson M, Johnson BE, Janne PA. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res 2004, 64:7241-7244. 10.1158/0008-5472.CAN-04-1905, 15492241.
3. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388. 10.1056/NEJMoa0909530, 20573926.
4. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DA. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102(21):7665-7670. 10.1073/pnas.0502860102, 1129023, 15897464.
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311. 10.1073/pnas.0405220101, 516528, 15329413.
6. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104(52):20932-20937. 10.1073/pnas.0710370104, 2409244, 18093943.
7. Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006, 12:5764-5769. 10.1158/1078-0432.CCR-06-0714, 17020982.
8. Pedersen MW, Pedersen N, Ottesen LH, Poulsen HS. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 2005, 93:915-923. 10.1038/sj.bjc.6602793, 2361662, 16189524.
9. Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006, 66(6):3162-3168. 10.1158/0008-5472.CAN-05-3757, 16540667.
10. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier LL. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 2003, 197(10):1245-1253. 10.1084/jem.20021973, 2193789, 12756263.
11. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005, 11:181-187. 10.1016/j.bbmt.2004.11.019, 15744236.
12. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol 2001, 29:1157-1168. 10.1016/S0301-472X(01)00696-8, 11602317.
13. Raulet DH, Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009, 9:568-580. 10.1038/nri2604, 3017432, 19629084.
14. Coupland LA, Chong BH, Parish CR. Platelets and p-selectin control tumor cell metastasis in an organ-specific manner and independently of NK cells. Cancer Res 2012, 72(18):4662-4671. 10.1158/0008-5472.CAN-11-4010, 22836751.
15. Elboim M, Gazit R, Gur C, Ghadially H, Betser-Cohen G, Mandelboim O. Tumor immunoediting by NKp46. J Immunol 2010, 184:5637-5644. 10.4049/jimmunol.0901644, 20404273.
16. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Hoglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Karre K, Shibuya A, Carbone E, Colucci F. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 2009, 119:1251-1263. 10.1172/JCI36022, 2673866, 19349689.
17. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004, 23:255-259. 10.1038/sj.emboj.7600019, 1271745, 14685277.
18. Cerwenka A, Baron JL, Lanier LL. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001, 98:11521-11526. 10.1073/pnas.201238598, 58762, 11562472.
19. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-171. 10.1038/35093109, 11557981.
20. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007, 7:329-339. 10.1038/nri2073, 17438573.
21. Tsukerman P, Stern-Ginossar N, Gur C, Glasner A, Nachmani D, Bauman Y, Yamin R, Vitenshtein A, Stanietsky N, Bar-Mag T, Lankry D, Mandelboim O. MiR-10b downregulates the stress-induced cell surface molecule MICB, a critical ligand for cancer cell recognition by natural killer cells. Cancer Res 2012, 72(21):1-10.
22. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005, 65(14):6321-6329. 10.1158/0008-5472.CAN-04-4252, 16024634.
23. Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny NJ, Lutz CT. Proteasome regulation of ULBP1 transcription. J Immunol 2009, 182:6600-6609. 10.4049/jimmunol.0801214, 2748925, 19414815.
24. Sutlu T, Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009, 266:154-181. 10.1111/j.1365-2796.2009.02121.x, 19614820.
25. Wilson EB, El-Jawhari JJ, Neilson AL, Hall GD, Melcher AA, Meade JL. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One 2011, 6(9):e22842. 10.1371/journal.pone.0022842, 3167809, 21909397.
26. Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z. Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol 2008, 180:7249-7258.
27. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, Balsamo M, Conte R, Benelli R, Minghelli S, Solari N, Gualco M, Queirolo P, Moretta L, Mingari MC. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012, 72(6):1407-1415. 10.1158/0008-5472.CAN-11-2544, 22258454.
28. Buchser WJ, Laskow TC, Pavlik PJ, Lin HM, Lotze MT. Cell-mediated autophagy promotes cancer cell survival. Cancer Res 2012, 72:2970-2979. 10.1158/0008-5472.CAN-11-3396, 3505669, 22505650.
29. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, DeMatteo RP. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17(9):1094-1100. 10.1038/nm.2438, 3278279, 21873989.
30. Borg C, Terme M, Taieb J, Menard C, Flament C, Robert C, Maruyama K, Wakasugi H, Angevin E, Thielemans K, Le Cesne A, Chung-Scott V, Lazar V, Tchou I, Crepineau F, Lemoine F, Bernard J, Fletcher JA, Turhan A, Blay JY, Spatz A, Emile JF, Heinrich MC, Mecheri S, Tursz T, Zitvogel L. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004, 114:379-388. 489961, 15286804.
31. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004, 294:15-22. 10.1016/j.jim.2004.08.008, 15604012.
32. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005, 175:1636-1642.
33. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De Libero G, Wodnar-Filipowicz A. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 2005, 105:3615-3622. 10.1182/blood-2004-07-2585, 15657183.
34. Kim H, Kim SH, Kim MJ, Kim SJ, Park SJ, Chung JS, Bae JH, Kang CD. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells. J Immunother 2011, 34:372-381. 10.1097/CJI.0b013e31821b724a, 21499124.
35. Haura EB, Zheng Z, Song L, Cantor A, Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005, 11:8288-8294. 10.1158/1078-0432.CCR-05-0827, 16322287.
36. Kim HP, Han SW, Kim SH, Im SA, Oh DY, Bang YJ, Kim TY. Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells. Mol Cancer Ther 2008, 7(3):607-615. 10.1158/1535-7163.MCT-07-2068, 18347147.
37. Ihara S, Kida H, Arase H, Tripathi LP, Chen YA, Kimura T, Yoshida M, Kashiwa Y, Hirata H, Fukamizu R, Inoue R, Hasegawa K, Goya S, Takahashi R, Minami T, Tsujino K, Suzuki M, Kohmo S, Inoue K, Nagatomo I, Takeda Y, Kijima T, Mizuguchi K, Tachibana I, Kumanogoh A. Inhibitory roles of signal transducer and activator of transcription 3 in antitumor immunity during carcinogen-induced lung tumorigenesis. Cancer Res 2012, 72(12):2990-2999. 10.1158/0008-5472.CAN-11-4062, 22659452.
38. Ramakrishnan R, Huang C, Cho HI, Lloyd M, Johnson J, Ren X, Altiok S, Sullivan D, Weber J, Celis E, Gabrilovich DI. Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy. Cancer Res 2012, 72:5483-5493. 10.1158/0008-5472.CAN-12-2236, 22942258.
39. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol 2009, 183:4921-4930. 10.4049/jimmunol.0901226, 19801517.
40. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol 2012, 189:1360-1371. 10.4049/jimmunol.1200796, 22730533.
41. Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002, 168:671-679.
42. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013, 19(5):1044-1053. 10.1158/1078-0432.CCR-12-2065, 23460535.
43. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, Colevas AD, Weng WK, Clarke MF, Carlson RW, Stockdale FE, Mollick JA, Chen L, Levy R. Stimulation of natural killer cells with a CD137- specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012, 122(3):1066-1075. 10.1172/JCI61226, 3287235, 22326955.
44. Flaig RM, Stark S, Watzl C. Cutting edge: NTB-A activates NK cells via homophilic interaction. J Immunol 2004, 172(11):6524-6527.
45. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, Phillips JH. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 1996, 4(6):573-581. 10.1016/S1074-7613(00)70060-4, 8673704.
46. Osaki T, Saito H, Yoshikawa T, Matsumoto S, Tatebe S, Tsujitani S, Ikeguchi M. Decreased NKG2D expression on CD8+ T cell is involved in immune evasion in patients with gastric cancer. Clin Cancer Res 2007, 13:382-387. 10.1158/1078-0432.CCR-06-1454, 17255258.
47. Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, Soo RA, Christensen JG, Lee JH, Cho BC. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 2012, 11(10):2254-2264. 10.1158/1535-7163.MCT-12-0311, 22891040.
48. Sumpter TL, Dangi A, Matta BM, Huang C, Stolz DB, Vodovotz Y, Thomson AW, Gandhi CR. Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO. J Immunol 2012, 189:3848-3858. 10.4049/jimmunol.1200819, 22962681.